At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 300 enrolled
Drug / intervention
Xalatan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 8-WEEK, RANDOMIZED, DOUBLE-MASKED, PARALLEL GROUP, PHASE III STUDY COMPARING THE EFFICACY AND SAFETY OF XALACOM AND XALATAN IN PATIENTS WITH PRIMARY OPEN ANGLE GLAUCOMA (POAG) OR OCULAR HYPERTENSION (OH)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.·interventional·Posted Oct 2, 2006·Updated Sep 8, 2021
In Brief
A Phase 3 clinical trial evaluating Xalatan and Xalacom for Glaucoma and Ocular Hypertension. Completed, enrolled 300 participants across 54 sites.
Detailed Summary
This study will examine the efficacy and safety of Xalacom comparing with those of Xalatan in Japanese patients with POAG or OH, in order to show superiority of Xalacom over Xalatan in efficacy and similarity of safety between Xalacom and Xalatan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Ocular Hypertension
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2006
Enrollment StartNov 2006
Primary CompletionOct 2007
TodayJul 2026
First PostedOct 2, 2006
Enrollment StartNov 14, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 19.8 years ago
Interventions
Xalatandrug
latanoprost 0.005%, one rop once daily in evening
Xalacomdrug
latanoprost 0.005% adn timolol 0.5%, one drop, once daily